Pharmaceutical prior art challenge - montelukast sodium

REQUEST # 30680-S1-01
Pharmaceutical Prior Art Challenge – Montelukast Sodium
Requesting Organization:
: February 20, 2009
MANAGER: Kevin C. Stark, Ph.D.
$50,000 Reward for legitimizing the validity of patents based on
technical literature research. If one or more references show a
patent to be invalid, then the respondent who found the research REQUEST DESCRIPTION
patent is invalid. Sending in research and all activities on the website also earn Points towards seeks public literature about montelukast sodium, profit sharing by users of about 5% of Article the active ingredient in Singulair™. Public literature for this project can be dated no later A brief introduction on this project is below, and more information on this patent study is online at: Article One Partners uses the power of the global online community to discover public literature (called Prior Art) that can legitimize or invalidate selected patents. The patents, the Latest Date for the public literature and details about the patents BACKGROUND SUMMARY
are described in Patent Studies. The Patent The active ingredient in Singulair, montelukast Study for this challenge is MRK 473. Learn more
sodium, is a selective and orally active leukotriene receptor antagonist that inhibits the Montelukast sodium is described by the structural RESPONDING TO THIS REQUEST
formula in Figure 1 above, CAS number [151767- If you can apply your knowledge, search skills or 02-1] and one of its full IUPAC chemical names network of referrals to identify relevant prior art, is Sodium 1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2- quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1- Responses are submitted using the Response methylethyl)phenyl]propyl]thio]methyl]cyclopropaneac form provided in the Study. Their website has more information on this particular challenge and defines what prior art is, and where to find it. The Singulair patent has “composition” claims Respondents are required to register online with and “method” claims. A composition claim is one that covers a chemical structure or formulation regardless of what it may be used for. A method A $50,000 reward will be distributed to the claim covers particular use(s) of the composition. respondent who is the first submitter of prior art The Singulair patent also has claims to the used by Article One to form an opinion that the combination of the claimed composition and 23611 Chagrin Blvd., Suite 320, Cleveland, OH 44122 • 216-295-4800 • RFP format and graphics Copyright 2007 NineSigma, Inc NineSigma Request # 30680-S1-01
Pharmaceutical Prior Art Challenge – Montelukast Sodium
another compound, for example, a non-steroidal anti-inflammatory drug (NSAID). Relevant prior art includes: 1. disclosure of the composition shown in 2. disclosure of the compositions shown in the patent (note there is a correction to the formula of the composition of claim 7; see the pdf copy of the patent online); 3. use of the composition to treat asthma; 4. use of the composition to treat synthesis, the action, or the release of SRS-A or leukotrienes. 23611 Chagrin Blvd., Suite 320, Cleveland, OH 44122 • 216-295-4800 •


The MPS Spring Symposium On Psychopharmacology On March 23, 2013, MPS members and guests—75 of us—attended “Psychopharmacology: Updates, Advances, and New Information” at Sheppard Pratt in Towson. Neil Sandson, MD led off with “Atypical Antipsychotics: What’s New?” His opening “caveats” included “Newer often/usually does not mean better.”, “Novelty in itself should not


BETTER HOME PRODUCTS SOMA COLLECTION SPECIFICATIONS ITEM# 20188CH - Passage Set Grade III tubular passage set. All metal components Door Prep - Crossbore 2 1/8", Edge Bore 1", Latch Face 1"x2 1/4" Door Thickness - 1 3/8" to 1 3/4" Function : Both levers always free Strike - Full lip radius corner

Copyright © 2010-2014 Drug Shortages pdf